Related references
Note: Only part of the references are listed.1st International consensus guidelines for advanced breast cancer (ABC 1)
F. Cardoso et al.
BREAST (2012)
2LBA Fulvestrant Alone or with Concomitant Anastrozole Vs Exemestane Following Progression On Non-steroidal Aromatase Inhibitor – First Results of the SoFEa Trial (CRUKE/03/021 & CRUK/09/007) (ISRCTN44195747)
S. Johnston et al.
EUROPEAN JOURNAL OF CANCER (2012)
Reversing Hormone Resistance: Have We Found the Golden Key?
Hope S. Rugo et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study
Thomas Bachelot et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
BOLERO-2-will this change practice in advanced breast cancer?
Stephen R. D. Johnston
BREAST CANCER RESEARCH (2012)
Mechanisms of Endocrine Resistance in Breast Cancer
C. Kent Osborne et al.
ANNUAL REVIEW OF MEDICINE, VOL 62, 2011 (2011)
Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer
Guy Jerusalem et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Overcoming breast cancer drug resistance with mTOR inhibitors. Could it be a myth or a real possibility in the short-term future?
Nadia Margariti et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
An epigenetic vicious cycle of DNMT, protein Tyrosine phosphatase receptor type R, and the MAPK pathway in cancer metastasis
Po-Hsuan Su et al.
CANCER RESEARCH (2011)
Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma
Camillo Porta et al.
EUROPEAN JOURNAL OF CANCER (2011)
Targeted therapies for breast cancer
Michaele J. Higgins et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Phase I/II Study of Trastuzumab in Combination With Everolimus (RAD001) in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Based Therapy
Phuong K. Morrow et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
mTOR: from growth signal integration to cancer, diabetes and ageing
Roberto Zoncu et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2011)
Clinical presentation and management of mTOR inhibitor-associated stomatitis
Marcio Augusto de Oliveira et al.
ORAL ONCOLOGY (2011)
Noninfectious Pneumonitis after Everolimus Therapy for Advanced Renal Cell Carcinoma
Dorothy A. White et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2010)
Phase 3 Trial of Everolimus for Metastatic Renal Cell Carcinoma Final Results and Analysis of Prognostic Factors
Robert J. Motzer et al.
CANCER (2010)
Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer
Jan C. Buckner et al.
INVESTIGATIONAL NEW DRUGS (2010)
Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer
Todd W. Miller et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Phase I Study of Everolimus Plus Weekly Paclitaxel and Trastuzumab in Patients With Metastatic Breast Cancer Pretreated With Trastuzumab
Fabrice Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor-Positive Advanced Breast Cancer
Angelo Di Leo et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A 2009 Update on the Treatment of Patients with Hormone Receptor-Positive Breast Cancer
Susan J. Cleator et al.
CLINICAL BREAST CANCER (2009)
Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163
Susan L. Ellard et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor-Positive Breast Cancer
Jose Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
David M. Nathan et al.
DIABETES CARE (2009)
Rational Management of Endocrine Resistance in Breast Cancer A Comprehensive Review of Estrogen Receptor Biology, Treatment Options, and Future Directions
Sara A. Hurvitz et al.
CANCER (2008)
Rosiglitazone no longer recommended
[Anonymous]
LANCET (2008)
The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: Results of a phase I study with pharmacokinetics
Ahmad Awada et al.
EUROPEAN JOURNAL OF CANCER (2008)
Double-blind, Randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: Results from EFECT
Stephen Chia et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: A phase I tumor pharmacodynamic study in patients with advanced solid tumors
Josep Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Putting Evidence Into Practice®:: Evidence-based interventions for the management of oral mucostis
Debra J. Harris et al.
CLINICAL JOURNAL OF ONCOLOGY NURSING (2008)
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer
Katrien Berns et al.
CANCER CELL (2007)
Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells
Wei Yue et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2007)
Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling
M. Beeram et al.
ANNALS OF ONCOLOGY (2007)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer
Daniel Cho et al.
CLINICAL CANCER RESEARCH (2007)
The effectiveness of commonly used mouthwashes for the prevention of chemotherapy-induced oral mucositis: a systematic review
C. M. J. Potting et al.
EUROPEAN JOURNAL OF CANCER CARE (2006)
Preventive intervention possibilities in radiotherapy- and chemotherapy-induced oral mucositis: Results of meta-analyses
M. A. Stokman et al.
JOURNAL OF DENTAL RESEARCH (2006)
Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus
I. Duran et al.
EUROPEAN JOURNAL OF CANCER (2006)
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Reuben J. Shaw et al.
NATURE (2006)
Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer
S Chan et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer
A Boulay et al.
CLINICAL CANCER RESEARCH (2005)
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma
LH Saal et al.
CANCER RESEARCH (2005)
Somatic mutation and gain of copy number of PIK3CA in human breast cancer
GJ Wu et al.
BREAST CANCER RESEARCH (2005)
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
Y Nagata et al.
CANCER CELL (2004)
The PIK3CA gene is mutated with high frequency in human breast cancers
KE Bachman et al.
CANCER BIOLOGY & THERAPY (2004)
Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity
LA DeGraffenried et al.
CLINICAL CANCER RESEARCH (2004)
Share Paper
